Loading
A phase 2 trial of HS-20093, Rezvilutamide, Abiraterone acetate in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer is a phase 2 interventional study registered as NCT07230106 by Jiangsu HengRui Medicine Co., Ltd., with 218 participants planned, started 2025-12-08 and due to reach its primary completion in 2028-12. Interventions recorded: HS-20093 for Injection, SHR3680 Tablet, Abiraterone Tablet, SHR2554 Tablet, Enzalutamide Tablet. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.